Overview

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo
Phase:
Phase 2
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Gedeon Richter Ltd.
Treatments:
Cariprazine